Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
DBV Technologies S.A. DBVT
$2.12
+$0.31 (14.59%)
На 18:00, 12 мая 2023
Ранг: 3
Ключевые показатели
-
Marketcap
332722844.00000000
-
week52high
3.43
-
week52low
1.08
-
Revenue
4800000
-
P/E TTM
-2
-
Beta
1.25610600
-
EPS
-0.64000000
-
Last Dividend
0.00000000
-
Next Earnings Date
08 мая 2023 г. в 04:00
Описание компании
DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product, which has completed Phase III clinical trial for the treatment of peanut allergies in 4 to 11 years of age children, adolescents, and adults. The milk-induced company is also developing Viaskin Milk that is in Phase I/II clinical trial for the treatment of Immunoglobulin E (IgE) mediated cow's milk protein allergy (CMPA); Viaskin Egg, a pre-clinical stage product for the treatment of hen's egg allergy; and booster vaccine for Bordetella pertussis. Its other earlier stage research programs include a vaccine for the respiratory syncytial virus, as well as treatments for Crohn's disease, celiac disease, and type I diabetes. The company has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Montrouge, France.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| JMP Securities | Market Outperform | Market Outperform | 21 дек 2021 г. |
| HC Wainwright & Co. | Buy | Buy | 21 дек 2021 г. |
| Morgan Stanley | Equal-Weight | Equal-Weight | 05 авг 2020 г. |
| HC Wainwright & Co. | Buy | Buy | 05 авг 2020 г. |
| Citigroup | Buy | Buy | 06 апр 2020 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| BAKER BROS. ADVISORS LP | A | 11732979 | 11732979 | 13 июн 2022 г. |
| BAKER BROS. ADVISORS LP | A | 1383352 | 1383352 | 13 июн 2022 г. |
| BAKER BROS. ADVISORS LP | A | 14575984 | 10622568 | 13 июн 2022 г. |
| BAKER BROS. ADVISORS LP | A | 1585054 | 1252432 | 13 июн 2022 г. |
| Robitaille Sebastien | A | 51000 | 51000 | 22 ноя 2021 г. |
| Robitaille Sebastien | A | 28500 | 5000 | 22 ноя 2021 г. |
| Mohideen Pharis | A | 95400 | 95400 | 22 ноя 2021 г. |
| Mohideen Pharis | A | 24200 | 8700 | 22 ноя 2021 г. |
| Tasse Daniel | A | 274000 | 274000 | 22 ноя 2021 г. |
| DE ROSEN MICHEL | A | 6837 | 6837 | 10 июн 2021 г. |
Новостная лента
Why Shares of DBV Technologies Jumped Thursday
The Motley Fool
11 мая 2023 г. в 15:31
The company's peanut allergy treatment patch could have a wide impact. DBV Technologies currently has no marketed products.
DBV Technologies to Participate in Upcoming Investor Conference
GlobeNewsWire
09 мая 2023 г. в 16:30
Montrouge, France, May 9, 2023 D BV Technologies to Participate in Upcoming Investor Conference DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced its participation in the JMP Securities Life Sciences Conference taking place May 15-16 in New York, NY. Daniel Tassé, Chief Executive Officer, will make a company presentation on Monday, May 15, 2023 at 9:00am ET, as well as participate in one-on-one investor meetings throughout the day.
7 Penny Stocks Sitting in the Sweet Spot
InvestorPlace
26 мар 2023 г. в 14:03
While penny stocks almost always attract investors' attention at some point, they're also wildly unpredictable and risky. Yes, some people do enjoy lifechanging profitability.
DBV Technologies S.A. (DBVT) Q4 2022 Earnings Call Transcript
Seeking Alpha
03 мар 2023 г. в 19:13
DBV Technologies S.A. (NASDAQ:DBVT ) Q4 2022 Results Conference Call March 2, 2023 5:00 PM ET Company Participants Anne Pollak - Head IR Daniel Tassé - CEO Sébastien Robitaille - CFO Pharis Mohideen - Chief Medical Officer Conference Call Participants Jon Wolleben - JMP Operator Good day, and welcome to the DBV Technologies Full Year 2022 Financial Results Conference Call.
DBV Technologies to Report Full Year 2022 Financial Results and Business Updates on March 2, 2023
GlobeNewsWire
27 февр 2023 г. в 01:30
Montrouge, France, February 27, 2023